279 related articles for article (PubMed ID: 25039150)
21. Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model.
Dai J; Chen EQ; Bai L; Gong DY; Zhou QL; Cheng X; Huang FJ; Tang H
Virol J; 2012 Nov; 9():280. PubMed ID: 23171829
[TBL] [Abstract][Full Text] [Related]
22. [Study on the differences of two mouse models of hepatitis B virus infection by transduction with rAAV8-1. 3HBV].
Wang G; Dong XY; Tian WH; Yu CJ; Zheng G; Gao J; Wang GJ; Wei GC; Zhou YS; Wu XB
Bing Du Xue Bao; 2012 Sep; 28(5):541-7. PubMed ID: 23233931
[TBL] [Abstract][Full Text] [Related]
23. KNK437 Inhibits Replication and Transcription of the Hepatitis B Virus.
Hu K; Huang Y; Mu J; Cheng Z; Zhu X
Bing Du Xue Bao; 2017 Jan; 33(1):24-35. PubMed ID: 30702818
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo anti-hepatitis B virus activities of the lignan nirtetralin B isolated from Phyllanthus niruri L.
Liu S; Wei W; Li Y; Lin X; Shi K; Cao X; Zhou M
J Ethnopharmacol; 2014 Nov; 157():62-8. PubMed ID: 25260580
[TBL] [Abstract][Full Text] [Related]
25. [Comparative analysis of hepatitis B virus large protein, hepatitis B virus-DNA and Pre-S1 antigen in evaluating serum hepatitis B virus replication].
Xia F; Xu YH; Zheng MJ; Wang XL
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jun; 51(6):501-505. PubMed ID: 28592093
[No Abstract] [Full Text] [Related]
26. [A construct competent to support the replication of hepatitis B virus of genotype B].
Li L; Zhang ZH; Shen H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):16-20. PubMed ID: 19203445
[TBL] [Abstract][Full Text] [Related]
27. Antiviral effects of a niobium-substituted heteropolytungstate on hepatitis B virus-transgenic mice.
Li Q; Zhang H; Qi Y; Wang J; Li J; Niu J
Drug Dev Res; 2019 Dec; 80(8):1062-1070. PubMed ID: 31396981
[TBL] [Abstract][Full Text] [Related]
28. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
[TBL] [Abstract][Full Text] [Related]
29. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication.
Yang J; Bo XC; Ding XR; Dai JM; Zhang ML; Wang XH; Wang SQ
J Viral Hepat; 2006 Mar; 13(3):158-65. PubMed ID: 16475991
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of anti-hepatitis B virus (HBV) drugs using the HBV transgenic mouse: application of the semiquantitative polymerase chain reaction (PCR) for serum HBV DNA to monitor the drug efficacy.
Kajino K; Kamiya N; Yuasa S; Takahara T; Sakurai J; Yamamura Ki; Hino O
Biochem Biophys Res Commun; 1997 Dec; 241(1):43-8. PubMed ID: 9405231
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.
Tseng TC; Liu CJ; Yang WT; Chen CL; Yang HC; Su TH; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2014 Jun; 29(6):1242-9. PubMed ID: 24384028
[TBL] [Abstract][Full Text] [Related]
32. Specific anti-viral effects of RNA interference on replication and expression of hepatitis B virus in mice.
Wu Y; Huang AL; Tang N; Zhang BQ; Lu NF
Chin Med J (Engl); 2005 Aug; 118(16):1351-6. PubMed ID: 16157029
[TBL] [Abstract][Full Text] [Related]
33. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
[TBL] [Abstract][Full Text] [Related]
34. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
35. Biological characteristics of the A1762T/G1764A mutant strain of hepatitis B virus in vivo.
Leng XH; Chen EQ; Du LY; Bai L; Gong DY; Cheng X; Huang FJ; Tang H
Mol Med Rep; 2015 Oct; 12(4):5141-8. PubMed ID: 26165271
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from Phyllanthus niruri L.
Liu S; Wei W; Shi K; Cao X; Zhou M; Liu Z
J Ethnopharmacol; 2014 Sep; 155(2):1061-7. PubMed ID: 25009077
[TBL] [Abstract][Full Text] [Related]
37. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation.
Wei ZQ; Zhang YH; Ke CZ; Chen HX; Ren P; He YL; Hu P; Ma DQ; Luo J; Meng ZJ
World J Gastroenterol; 2017 Sep; 23(34):6252-6260. PubMed ID: 28974891
[TBL] [Abstract][Full Text] [Related]
38. [Role of tumor necrosis factor-alpha in the anti-HBV activity of tetracycline].
Ni Y; Jiang F; Xu H; Zeng T; Lei Y; Chen Y; Zhou Z; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):213-8. PubMed ID: 24824125
[TBL] [Abstract][Full Text] [Related]
39. Mucroporin-M1 inhibits hepatitis B virus replication by activating the mitogen-activated protein kinase (MAPK) pathway and down-regulating HNF4α in vitro and in vivo.
Zhao Z; Hong W; Zeng Z; Wu Y; Hu K; Tian X; Li W; Cao Z
J Biol Chem; 2012 Aug; 287(36):30181-90. PubMed ID: 22791717
[TBL] [Abstract][Full Text] [Related]
40. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210.
Zhang GL; Li YX; Zheng SQ; Liu M; Li X; Tang H
Antiviral Res; 2010 Nov; 88(2):169-75. PubMed ID: 20728471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
